• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

卵巢肿瘤囊液中的组织蛋白酶 B、L 和半胱氨酸蛋白酶抑制剂 C。

Cathepsins B, L and cystatin C in cyst fluid of ovarian tumors.

机构信息

Department of Obstetrics and Gynecology, Radboud University Nijmegen Medical Centre, The Netherlands.

出版信息

J Cancer Res Clin Oncol. 2010 May;136(5):771-8. doi: 10.1007/s00432-009-0716-z. Epub 2009 Nov 14.

DOI:10.1007/s00432-009-0716-z
PMID:19915865
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2841751/
Abstract

INTRODUCTION

In cancer, an extracellular and membrane bound localization of cathepsins contribute to the invasion of tumor cells at the basement membrane.

METHODS

This is the first study that explored levels of cathepsins B (CatB), L (CatL) and their inhibitor cystatin C (CysC) in the cystic fluid (CF) of ovarian tumors (n = 110).

RESULTS

CF contained considerable amounts of CatB, CatL and CysC. Remarkable differences in CatB and CatL and CysC CF levels were found between different histopathological tumor subtypes. Levels of CatB and CysC were significantly higher in CF of malignant serous tumors compared to those found in benign serous tumors (p = 0.010 and p = 0.001 respectively), whereas levels of CatL were significantly higher in CF of malignant mucinous tumors compared to those found in benign mucinous tumors (p = 0.035). CatB and CysC showed a strong correlation in the group of patients with malignant serous tumors (p < 0.001; R = 0.921) suggesting that the increase in CatB might be balanced by a corresponding increase in CysC.

CONCLUSION

Further studies are warranted to investigate cathepsins as possible prognostic biomarkers for the aggressiveness of ovarian cancer.

摘要

简介

在癌症中，组织蛋白酶的细胞外和膜结合定位有助于肿瘤细胞在基底膜处的侵袭。

方法

这是首次研究探索组织蛋白酶 B（CatB）、L（CatL）及其抑制剂胱抑素 C（CysC）在卵巢肿瘤囊液（CF）中的水平（n = 110）。

结果

CF 中含有相当数量的 CatB、CatL 和 CysC。不同组织病理学肿瘤亚型的 CF 中 CatB 和 CatL 和 CysC 水平存在显著差异。与良性浆液性肿瘤相比，恶性浆液性肿瘤的 CF 中 CatB 和 CysC 水平显著升高（p = 0.010 和 p = 0.001），而恶性黏液性肿瘤的 CF 中 CatL 水平显著升高（p = 0.035）。在恶性浆液性肿瘤患者组中，CatB 和 CysC 之间存在强烈相关性（p < 0.001；R = 0.921），表明 CatB 的增加可能由 CysC 的相应增加所平衡。

结论

有必要进一步研究组织蛋白酶作为卵巢癌侵袭性的可能预后生物标志物。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/22bb/11828310/fc6667b6cad2/432_2009_716_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/22bb/11828310/9d113507a8e7/432_2009_716_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/22bb/11828310/fc6667b6cad2/432_2009_716_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/22bb/11828310/9d113507a8e7/432_2009_716_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/22bb/11828310/fc6667b6cad2/432_2009_716_Fig2_HTML.jpg

相似文献

1
Cathepsins B, L and cystatin C in cyst fluid of ovarian tumors.卵巢肿瘤囊液中的组织蛋白酶 B、L 和半胱氨酸蛋白酶抑制剂 C。
J Cancer Res Clin Oncol. 2010 May;136(5):771-8. doi: 10.1007/s00432-009-0716-z. Epub 2009 Nov 14.
2
Prognostic significance of cathepsins B and L in primary human breast cancer.
J Clin Oncol. 1998 Mar;16(3):1013-21. doi: 10.1200/JCO.1998.16.3.1013.
3
A mechanistic model to predict effects of cathepsin B and cystatin C on β-amyloid aggregation and degradation.一种预测组织蛋白酶 B 和半胱氨酸蛋白酶抑制剂 C 对β-淀粉样蛋白聚集和降解影响的机制模型。
J Biol Chem. 2017 Dec 22;292(51):21071-21082. doi: 10.1074/jbc.M117.811448. Epub 2017 Oct 18.
4
The balance between extracellular cathepsins and cystatin C is of importance for ovarian cancer.细胞外组织蛋白酶与胱抑素 C 之间的平衡对卵巢癌具有重要意义。
Eur J Clin Invest. 2010 Jul;40(7):591-9. doi: 10.1111/j.1365-2362.2010.02305.x. Epub 2010 May 12.
5
Increasing Cystatin C and Cathepsin B in Serum of Colorectal Cancer Patients.结直肠癌患者血清中胱抑素C和组织蛋白酶B水平升高。
Clin Lab. 2017 Feb 1;63(2):365-371. doi: 10.7754/Clin.Lab.2016.160706.
6
Comparison of potential biological markers cathepsin B, cathepsin L, stefin A and stefin B with urokinase and plasminogen activator inhibitor-1 and clinicopathological data of breast carcinoma patients.组织蛋白酶B、组织蛋白酶L、丝抑素A和丝抑素B与尿激酶及纤溶酶原激活物抑制剂-1作为潜在生物标志物的比较及乳腺癌患者的临床病理数据
Cancer Detect Prev. 2002;26(1):42-9. doi: 10.1016/s0361-090x(02)00015-6.
7
Cathepsin B, a prognostic indicator in lymph node-negative breast carcinoma patients: comparison with cathepsin D, cathepsin L, and other clinical indicators.组织蛋白酶B，淋巴结阴性乳腺癌患者的预后指标：与组织蛋白酶D、组织蛋白酶L及其他临床指标的比较
Clin Cancer Res. 2000 Feb;6(2):578-84.
8
Tumor marker utility and prognostic relevance of cathepsin B, cathepsin L, urokinase-type plasminogen activator, plasminogen activator inhibitor type-1, CEA and CA 19-9 in colorectal cancer.组织蛋白酶B、组织蛋白酶L、尿激酶型纤溶酶原激活剂、纤溶酶原激活剂抑制剂-1、癌胚抗原和CA 19-9在结直肠癌中的肿瘤标志物效用及预后相关性
BMC Cancer. 2008 Jul 10;8:194. doi: 10.1186/1471-2407-8-194.
9
Overexpression of cystatin C in synovium does not reduce synovitis or cartilage degradation in established osteoarthritis.在已确诊的骨关节炎中，滑膜中胱抑素C的过表达并不能减轻滑膜炎或软骨降解。
Arthritis Res Ther. 2015 Jan 16;17(1):5. doi: 10.1186/s13075-015-0519-3.
10
Human papillomavirus type 16 does not require cathepsin L or B for infection.人乳头瘤病毒 16 型感染不需要组织蛋白酶 L 或 B。
J Gen Virol. 2013 Aug;94(Pt 8):1865-1869. doi: 10.1099/vir.0.053694-0. Epub 2013 May 15.

引用本文的文献

1
Spotlight on Proteases: Roles in Ovarian Health and Disease.蛋白酶聚焦：在卵巢健康与疾病中的作用
Cells. 2025 Jun 18;14(12):921. doi: 10.3390/cells14120921.
2
The PMA phorbol ester tumor promoter increases canonical Wnt signaling via macropinocytosis.PMA 佛波酯肿瘤促进剂通过巨胞饮作用增加经典 Wnt 信号通路。
Elife. 2023 Oct 30;12:RP89141. doi: 10.7554/eLife.89141.
3
Smart Delivery Systems Responsive to Cathepsin B Activity for Cancer Treatment.响应组织蛋白酶B活性的癌症治疗智能递送系统

本文引用的文献

1
Ovarian carcinoma subtypes are different diseases: implications for biomarker studies.卵巢癌亚型是不同的疾病：对生物标志物研究的启示。
PLoS Med. 2008 Dec 2;5(12):e232. doi: 10.1371/journal.pmed.0050232.
2
Early events in the pathogenesis of epithelial ovarian cancer.上皮性卵巢癌发病机制中的早期事件。
J Clin Oncol. 2008 Feb 20;26(6):995-1005. doi: 10.1200/JCO.2006.07.9970. Epub 2008 Jan 14.
3
Combined staining of TAG-72, MUC1, and CA125 improves labeling sensitivity in ovarian cancer: antigens for multi-targeted antibody-guided therapy.
Pharmaceutics. 2023 Jun 29;15(7):1848. doi: 10.3390/pharmaceutics15071848.
4
Ultrasensitive, multiplexed chemoproteomic profiling with soluble activity-dependent proximity ligation.基于可溶性活性依赖型邻近连接的超高灵敏、多重化学蛋白质组学分析。
Proc Natl Acad Sci U S A. 2019 Oct 22;116(43):21493-21500. doi: 10.1073/pnas.1912934116. Epub 2019 Oct 7.
5
Cystatin C deficiency suppresses tumor growth in a breast cancer model through decreased proliferation of tumor cells.胱抑素C缺乏通过降低肿瘤细胞增殖抑制乳腺癌模型中的肿瘤生长。
Oncotarget. 2017 Apr 24;8(43):73793-73809. doi: 10.18632/oncotarget.17379. eCollection 2017 Sep 26.
6
Increased phosphorylation of eIF2α in chronic myeloid leukemia cells stimulates secretion of matrix modifying enzymes.慢性粒细胞白血病细胞中eIF2α磷酸化增加会刺激基质修饰酶的分泌。
Oncotarget. 2016 Nov 29;7(48):79706-79721. doi: 10.18632/oncotarget.12941.
7
Targeting Cathepsin B for Cancer Therapies.靶向组织蛋白酶B用于癌症治疗
Horiz Cancer Res. 2015;56:23-40.
8
Screening and identification of small molecule inhibitors of ErbB2-induced invasion.筛选和鉴定 ErbB2 诱导侵袭的小分子抑制剂。
Mol Oncol. 2014 Dec;8(8):1703-18. doi: 10.1016/j.molonc.2014.07.004. Epub 2014 Jul 12.
9
Serum HE4, CA125, YKL-40, bcl-2, cathepsin-L and prediction optimal debulking surgery, response to chemotherapy in ovarian cancer.血清人附睾蛋白4、癌抗原125、YKL-40、bcl-2、组织蛋白酶L与卵巢癌最佳肿瘤细胞减灭术预测及化疗反应
J Ovarian Res. 2014 Jun 10;7:62. doi: 10.1186/1757-2215-7-62. eCollection 2014.
10
Effect of EGb761 on light-damaged retinal pigment epithelial cells.银杏叶提取物761对光损伤视网膜色素上皮细胞的影响。
Int J Ophthalmol. 2014 Feb 18;7(1):8-13. doi: 10.3980/j.issn.2222-3959.2014.01.02. eCollection 2014.
TAG-72、MUC1和CA125联合染色可提高卵巢癌的标记敏感性：用于多靶点抗体导向治疗的抗原。
J Histochem Cytochem. 2007 Aug;55(8):867-75. doi: 10.1369/jhc.7A7213.2007. Epub 2007 May 3.
4
CA125 expression pattern, prognosis and correlation with serum CA125 in ovarian tumor patients. From The Danish "MALOVA" Ovarian Cancer Study.卵巢肿瘤患者中CA125表达模式、预后及其与血清CA125的相关性。来自丹麦“MALOVA”卵巢癌研究。
Gynecol Oncol. 2007 Mar;104(3):508-15. doi: 10.1016/j.ygyno.2006.09.028. Epub 2006 Nov 17.
5
Ovarian cancer.卵巢癌
Crit Rev Oncol Hematol. 2006 Nov;60(2):159-79. doi: 10.1016/j.critrevonc.2006.03.004. Epub 2006 Oct 2.
6
Cystatin C as a potential marker for relapse in patients with non-Hodgkin B-cell lymphoma.胱抑素C作为非霍奇金B细胞淋巴瘤患者复发的潜在标志物。
Cancer Lett. 2007 Apr 18;248(2):192-7. doi: 10.1016/j.canlet.2006.07.004. Epub 2006 Sep 1.
7
A distinct molecular profile associated with mucinous epithelial ovarian cancer.与黏液性上皮性卵巢癌相关的独特分子特征。
Br J Cancer. 2006 Mar 27;94(6):904-13. doi: 10.1038/sj.bjc.6603003.
8
Intracellular proteolytic activity of cathepsin B is associated with capillary-like tube formation by endothelial cells in vitro.组织蛋白酶B的细胞内蛋白水解活性与体外内皮细胞形成毛细血管样管相关。
J Cell Biochem. 2006 Apr 15;97(6):1230-40. doi: 10.1002/jcb.20720.
9
Recent advances in endometriosis with emphasis on pathogenesis, molecular pathology, and neoplastic transformation.子宫内膜异位症的最新进展，重点在于发病机制、分子病理学和肿瘤转化。
Int J Gynecol Pathol. 2004 Oct;23(4):316-20. doi: 10.1097/01.pgp.0000139636.94352.89.
10
Serum level of cathepsin B and its density in men with prostate cancer as novel markers of disease progression.前列腺癌男性患者血清组织蛋白酶B水平及其密度作为疾病进展的新标志物。
Anticancer Res. 2004 Jul-Aug;24(4):2573-7.